In contrast, studies showed that Lck expression correlates with the sensitivity of CLL cells to pharmacological treatment and hence Lck is considered as a potential indicator of the response to CLL therapy and a target for the treatment of CLL [81,83]. The gene discussed is LCK; the disease is B-cell chronic lymphocytic leukemia.